Charts

10 Feb, 2024
09 Feb, 2024

News

13 Feb, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are a hot topic on Tuesday and we're diving into all of the biggest winners and losers this morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
30 Jan, 2024
Gainers SINTX Techs (NASDAQ:SINT) shares increased by 75.0% to $0.41 during Tuesday's after-market session. The market value of their ...
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 2:40 p.m. ET.
22 Jan, 2024
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced completion of enrollment in its CAHmelia-204 clinical trial of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH).
05 Jan, 2024
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported baseline characteristics of patients enrolled in the CAHmelia-203 and CAHmelia-204 clinical studies of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH).
04 Jan, 2024
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, upcoming milestones and strategic priorities for advancing tildacerfont for the treatment of adult and pediatric classic congenital adrenal hyperplasia (CAH).
20 Nov, 2023
Analysts have provided the following ratings for Spruce Biosciences (NASDAQ:SPRB) within the last quarter: Bullish Somewhat ...
13 Nov, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates.
02 Nov, 2023
Spruce Biosciences to Participate in the Jefferies London Healthcare Conference
20 Oct, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum ...
18 Oct, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced completion of target enrollment of 72 patients and closure of screening in the CAHmelia-203 clinical trial evaluating tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH) and provided updated anticipated milestones.
08 Sep, 2023
Gainers Biocept, Inc. (NASDAQ: BIOC) shares jumped 97.6% to $1.6608 after the company announced non-exclusive licensing agreement ...
Upgrades Wells Fargo upgraded the previous rating for TC Energy Corp (NYSE:TRP) from Underweight to Equal-Weight. TC Energy earned $0.71 ...
Over the past 3 months, 6 analysts have published their opinion on Spruce Biosciences (NASDAQ:SPRB) stock. These analysts are typically ...
Gainers Impel Pharmaceuticals Inc. (NASDAQ: IMPL) rose 41.3% to $0.54 in pre-market trading after falling 4% on Thursday. AGBA ...
B of A Securities cut the price target for DigitalOcean Holdings, Inc. (NYSE: DOCN) from $47 to $25. B of A Securities analyst ...
28 Aug, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, at 3:30 p.m. ET.
16 Aug, 2023
15:00
FinancialContent
Spruce Biosciences (NASDAQ:SPRB) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...
14 Aug, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates.
27 Jul, 2023
Gainers Mallinckrodt (AMEX:MNK) shares rose 77.8% to $2.24 during Thursday's pre-market session. The company's market cap stands at ...
24 Jul, 2023
Spruce Biosciences, Inc. (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
23 Jun, 2023
17:04
Seeking Alpha
12 Jun, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for the 105th Annual Meeting of the Endocrine Society (ENDO 2023) taking place June 15-18, 2023, in Chicago. In a poster presentation, the company will highlight the effect of tildacerfont on gonadotropins and testicular steroidogenesis in men with classic congenital adrenal hyperplasia (CAH).
25 May, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Percival Barretto-Ko to the company’s Board of Directors. Concurrently, Dina Chaya, Ph.D., has stepped down from the Board of Directors.
24 May, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Jefferies Healthcare Conference on June 9, 2023, at 9:30 a.m. ET.
22 May, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, was honored by the CARES Foundation, Inc. for its ongoing development of tildacerfont for patients with classic congenital adrenal hyperplasia (CAH). The CARES Foundation is the only U.S.-based nonprofit organization solely dedicated to improving the lives of the CAH patient community and seeks to advance quality health care. Spruce Biosciences’ Chief Executive Officer, Javier Szwarcberg, M.D., M.P.H., accepted the Corporate Partner Award at the 15th Annual Everyone CARES Gala held in New York City on May 20.
16 May, 2023
Within the last quarter, Spruce Biosciences (NASDAQ:SPRB) has observed the following analyst ratings: Bullish Somewhat ...
While Spruce Biosciences, Inc. ( NASDAQ:SPRB ) shareholders are probably generally happy, the stock hasn't had...
15 May, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the quarter ended March 31, 2023 and provided corporate updates.
04 May, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the Pediatric Endocrine Society (PES) 2023 Annual Meeting taking place May 5-8, 2023, in San Diego, Calif. Mitchell Geffner, M.D., will present findings on a retrospective analysis of completion rates for adult and pediatric congenital adrenal hyperplasia (CAH) studies.
02 May, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in May.
31 Mar, 2023
Spruce Biosciences, Inc. (SPRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
23 Mar, 2023
Over the past 3 months, 4 analysts have published their opinion on Spruce Biosciences (NASDAQ:SPRB) stock. These analysts are typically ...
Baird cut the price target for Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) from $14 to $11. Baird analyst Justin Kleber ...
16 Mar, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2022 and provided corporate updates.
28 Feb, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 2:40 PM ET.
22 Feb, 2023
The Dow Jones closed lower by around 700 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or ...
Gainers Windtree Therapeutics (NASDAQ:WINT) stock increased by 28.8% to $0.22 during Wednesday's pre-market session. The market value ...
09 Feb, 2023
Gainers Janux Therapeutics (NASDAQ:JANX) stock moved upwards by 27.8% to $22.83 during Thursday's after-market session. The market ...
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that it has entered into a definitive securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $53.6 million, before deducting offering expenses. The private placement includes participation from new and existing investors, including 5am Ventures, Abingworth, Armistice Capital, HealthCap, Novo Holdings A/S, RiverVest Venture Partners, and Rock Springs Capital.
01 Feb, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 2:20 p.m. ET.
09 Jan, 2023
Spruce Biosciences's (NASDAQ:SPRB) short percent of float has risen 17.3% since its last report. The company recently reported that ...
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for advancing tildacerfont in classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) rose 140.2% to $28.30 in pre-market trading after AstraZeneca announced plans to buy ...
06 Jan, 2023
Gainers Lucira Health (NASDAQ:LHDX) shares rose 29.5% to $0.51 during Friday's after-market session. Lucira Health's trading volume hit ...
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 700 points on Friday. The Dow traded up 2.14% ...
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review ...
Gainers Spruce Biosciences (NASDAQ:SPRB) stock increased by 85.6% to $2.32 during Friday's regular session. The current volume of 54.1 ...
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 550 points on Friday. The Dow traded up 1.69% ...
Gainers Spruce Biosciences (NASDAQ:SPRB) stock rose 80.0% to $2.25 during Friday's pre-market session. The market value of their ...
Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.
Spruce Biosciences Inc(NASDAQ: SPRB) andKaken Pharmaceutical Co. Ltdentered into anexclusive licensing ...
11 Nov, 2022
10 Aug, 2022
05 Jan, 2022
14:09
Seeking Alpha
16 Nov, 2021
15 Nov, 2021
10 Aug, 2021

Related Articles